Androgen Receptor Immunohistochemistry is Superior to PRAME for the Differentiation of Sebaceous Carcinoma From Primary Cutaneous Basaloid Mimics.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
ppublish
Résumé
Cutaneous sebaceous neoplasia comprises a spectrum of disease ranging from benign adenomas to malignant carcinomas. The hallmark of these lesions is sebaceous differentiation. However, poorly-differentiated sebaceous carcinoma (SC), which lacks significant overt sebaceous differentiation, can show morphologic overlap with a variety of other basaloid cutaneous neoplasms. The accurate classification of SC is essential not only for diagnosis, but also because of the potential association with Muir-Torre syndrome. Androgen receptor (AR) is a sensitive, but not entirely specific immunohistochemical marker that has been used for the diagnosis of SC. PReferentially expressed Antigen in MElanoma (PRAME) demonstrates strong cytoplasmic labeling of mature sebocytes and has been reported to be expressed in a variety of sebaceous neoplasms, including in the basaloid cell component. Therefore, we sought to compare the diagnostic use of cytoplasmic PRAME expression with that of AR for the distinction of SC from a cohort of basaloid cutaneous mimics; namely basal cell carcinoma, basaloid squamous cell carcinoma, pilomatricoma, cutaneous lymphadenoma, and extra-mammary Paget disease. We report that cytoplasmic PRAME expression is uncommon in poorly differentiated SC, and although specific, it shows very low sensitivity (22%). In contrast, AR was moderately sensitive (66%) and highly specific (92%) for the distinction of SC from basaloid mimics. These attributes, in addition to the nuclear expression of AR in the sebocytic and basaloid components of SC, suggest that AR is superior to PRAME for the diagnosis of SC.
Identifiants
pubmed: 38488347
doi: 10.1097/DAD.0000000000002496
pii: 00000372-202404000-00001
doi:
Substances chimiques
Receptors, Androgen
0
PRAME protein, human
0
Antigens, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-203Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Shalin SC, Lyle S, Calonje E, et al. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133–147.
Danialan R, Mutyambizi K, Aung P, et al. Challenges in the diagnosis of cutaneous adnexal tumours. J Clin Pathol. 2015;68:992–1002.
Ferreira I, Wiedemeyer K, Demetter P, et al. Update on the pathology, genetics and somatic landscape of sebaceous tumours. Histopathology. 2020;76:640–649.
Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19(suppl 2):S93–S126.
Flux K. Sebaceous neoplasms. Surg Pathol Clin. 2017;10:367–382.
Kazakov DV, Kutzner H, Spagnolo DV, et al. Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). Am J Dermatopathol. 2008;30:21–26.
Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999;21:426–431.
Ansai S, Takeichi H, Arase S, et al. Sebaceous carcinoma: an immunohistochemical reappraisal. Am J Dermatopathol. 2011;33:579–587.
Bourlond F, Velter C, Cribier B. Androgen receptor expression in epidermal and adnexal tumours. A3nn de Dermatologie de Vénéréologie. 2021;148:116–121.
Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME Expression in melanocytic tumors. Am J Surg Pathol. 2018;42:1456–1465.
Lezcano C, Jungbluth AA, Busam KJ. PRAME Immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin. 2021;14:165–175.
Donnell SA, LeBlanc RE, Yan S, et al. Comparison of adipophilin and recently introduced PReferentially expressed Antigen in MElanoma immunohistochemistry in the assessment of sebaceous neoplasms: a pilot study. J Cutan Pathol. 2021;48:1252–1261.
Goto K, Sugino T. Cytoplasmic expression of PMS2 (clone EP51), PRAME, and STAT6 (clone YE361) as a potential immunohistochemical finding for detection of sebocyte differentiation. J Cutan Pathol. 2021;48:1324–1327.
Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41:1–15.
Park SK, Park J, Kim HU, et al. Sebaceous carcinoma: clinicopathologic analysis of 29 cases in a tertiary hospital in Korea. J Korean Med Sci. 2017;32:1351–1359.
Battistella M, Balme B, Jullie ML, et al. Impact of expert pathology review in skin adnexal carcinoma diagnosis: analysis of 2573 patients from the French CARADERM network. Eur J Cancer. 2022;163:211–221.
Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol. 2007;13:301–319.
Tripathi R, Chen Z, Li L, et al. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75:1210–1215.
North JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018;9:1894.
North JP, Solomon DA, Golovato J, et al. Loss of ZNF750 in ocular and cutaneous sebaceous carcinoma. J Cutan Pathol. 2019;46:736–741.
Hazawa M, Lin DC, Handral H, et al. ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene. 2017;36:2243–2254.
Asadi-Amoli F, Khoshnevis F, Haeri H, et al. Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol. 2010;134:22–26.
Yang HM, Cabral E, Dadras SS, et al. Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol. 2008;30:549–554.
Heyl J, Mehregan D. Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol. 2008;35:40–45.
Plaza JA, Mackinnon A, Carrillo L, et al. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study. Am J Dermatopathol. 2015;37:809–821.
Ostler DA, Prieto VG, Reed JA, et al. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol. 2010;23:567–573.
Tjarks BJ, Pownell BR, Evans C, et al. Evaluation and comparison of staining patterns of factor XIIIa (AC-1A1), adipophilin and GATA3 in sebaceous neoplasia. J Cutan Pathol. 2018;45:1–7.
Oulès B, Deschamps L, Sohier P, et al. Diagnostic accuracy of GATA6 immunostaining in sebaceous tumors of the skin. Mod Pathol. 2023;36:100101.
Elsensohn A, Hanson J, Ferringer T. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin. J Cutan Pathol. 2021;48:1150–1155.
Kaczorowski M, Chłopek M, Kruczak A, et al. PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol. 2022;46:1467–1476.
Hrycaj SM, Szczepanski JM, Zhao L, et al. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis. Histopathology. 2022;81:818–825.
Wakefield C, Heffron CCBB. PRAME immunoexpression in benign fibroblasts: a diagnostic pitfall. Histopathology. 2022;80:1011–1013.
Krajisnik A, Gharavi NM, Faries MB, et al. Immunohistochemistry for preferentially expressed antigen in melanoma in the differential diagnosis of melanocytic lesions of the nail apparatus. Am J Dermatopathol. 2022;44:488–492.
Ng JKM, Choi PCL, Chow C, et al. PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures. Pathology. 2022;54:721–728.
Cazzato G, Colagrande A, Ingravallo G, et al. PRAME immuno-expression in cutaneous sebaceous carcinoma: a single institutional experience. J Clin Med. 2022;11:6936.
Monteagudo C, Fúnez R, Sánchez-Sendra B, et al. Cutaneous lymphadenoma is a distinct trichoblastoma-like lymphoepithelial tumor with diffuse androgen receptor immunoreactivity, Notch1 ligand in Reed-Sternberg-like cells, and common EGFR somatic mutations. Am J Surg Pathol. 2021;45:1382–1390.